P2, N=105, Recruiting, St. Joseph's Hospital and Medical Center, Phoenix | Not yet recruiting --> Recruiting

The combination of Bevacizumab and Fingolimod presents a promising treatment strategy for ovarian cancer.

P3, N=300, Recruiting, Viatris Innovation GmbH | Not yet recruiting --> Recruiting

P1, N=6, Recruiting, Viatris Innovation GmbH

P3, N=451, Active, not recruiting, Viatris Innovation GmbH | Recruiting --> Active, not recruiting

FTY720, an S1P receptor antagonist, significantly inhibits ER stress-induced IEC injury. Our findings highlight the pathogenic role of host SPHK1 in gastrointestinal injury during aGVHD and suggest that targeting SPHK1 could be a therapeutic strategy for managing this condition.

Molecular docking and dynamics simulations showed that R120P and F125S weaken binding affinity for natural agonist sphingosine-1-phosphate (S1P) and FTY720P, while antagonist W146 retained strong binding...Collectively, these findings identified high-risk nsSNPs in S1PR1 gene with potential structural and functional implications, particularly in diseases involving impaired receptor signaling. These findings enhanced our understanding of how specific nsSNPs can influence disease susceptibility, drug response, and receptor function, paving the way for precision medicine approaches in treating autoimmune and inflammatory disorders.

P2, N=15, Enrolling by invitation, Viatris Pharmaceuticals Co., Ltd. | Not yet recruiting --> Enrolling by invitation

P1, N=6, Active, not recruiting, Viatris Innovation GmbH | Not yet recruiting --> Active, not recruiting

P1, N=6, Not yet recruiting, Viatris Innovation GmbH

Depleting CD4+ T-cells, or blocking lymphocyte egress from the lymph nodes with FTY720, rescues tumor growth in mice with conditional deletion of Dnmt1 in ECs (Dnmt1iECKO) and dramatically shortens overall survival, whereas NK cells are dispensable...Finally, immune checkpoint blockade (ICB) administered to Dnmt1iECKO mice with experimental melanoma lung metastasis reduces tumor burden, with some mice showing tumor eradication. Our findings identify endothelial Dnmt1 as a key regulator of vascular-mediated anti-tumor immunity, providing a rationale for integrating epigenetic modulation of the vasculature with cancer immunotherapy regimens.